{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:51:56Z","timestamp":1792785116799,"version":"4.5.0"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100016114","name":"Zhejiang Medical Association","doi-asserted-by":"publisher","award":["2023ZYC-A11"],"award-info":[{"award-number":["2023ZYC-A11"]}],"id":[{"id":"10.13039\/501100016114","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pioneer and Leading Goose R&D Program of Zhejiang","award":["2025C02072"],"award-info":[{"award-number":["2025C02072"]}]},{"DOI":"10.13039\/100007835","name":"Wenzhou Medical University","doi-asserted-by":"publisher","award":["QNYC-105"],"award-info":[{"award-number":["QNYC-105"]}],"id":[{"id":"10.13039\/100007835","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Zhejiang Provincial Traditional Chinese Medicine Scientific Research Fund","award":["2022ZB215"],"award-info":[{"award-number":["2022ZB215"]}]},{"DOI":"10.13039\/501100007194","name":"Wenzhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["Y20220694"],"award-info":[{"award-number":["Y20220694"]}],"id":[{"id":"10.13039\/501100007194","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007194","name":"Wenzhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["Y2023162"],"award-info":[{"award-number":["Y2023162"]}],"id":[{"id":"10.13039\/501100007194","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["ZCLMS25H1606"],"award-info":[{"award-number":["ZCLMS25H1606"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Zhejiang Province Natural Science Foundation"},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"crossref","award":["Y-NESTLE2022QN-0427"],"award-info":[{"award-number":["Y-NESTLE2022QN-0427"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007194","name":"Wenzhou Municipal Science and Technology Bureau","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007194","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The First Affiliated Hospital of Wenzhou Medical University Young Talent Project","id":[{"id":"https:\/\/ror.org\/03cyvdv85","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2023RC201"],"award-info":[{"award-number":["2023RC201"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.canlet.2025.217808","type":"journal-article","created":{"date-parts":[[2025,5,18]],"date-time":"2025-05-18T17:54:19Z","timestamp":1747590859000},"page":"217808","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Ketogenesis instigates immune suppression in enzalutamide resistant prostate cancer via OTUD7B \u03b2-hydroxybutyrylation"],"prefix":"10.1016","volume":"625","author":[{"given":"Haoran","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqiang","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junkai","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moyang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangdie","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifa","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.canlet.2025.217808_bib1","first-page":"12","article-title":"Cancer statistics","volume":"74","author":"Siegel","year":"2024","journal-title":"Ca - Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.canlet.2025.217808_bib2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur. Urol."},{"issue":"6","key":"10.1016\/j.canlet.2025.217808_bib3","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","article-title":"Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents","volume":"34","author":"Fizazi","year":"2023","journal-title":"Ann. Oncol. : official journal of the European Society for Medical Oncology"},{"issue":"3","key":"10.1016\/j.canlet.2025.217808_bib4","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/endrev\/bnab002","article-title":"Hormonal therapy for prostate cancer","volume":"42","author":"Desai","year":"2021","journal-title":"Endocr. Rev."},{"issue":"26","key":"10.1016\/j.canlet.2025.217808_bib5","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"32","key":"10.1016\/j.canlet.2025.217808_bib6","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"issue":"4","key":"10.1016\/j.canlet.2025.217808_bib7","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.annonc.2020.02.002","article-title":"Epigenetic modulations and lineage plasticity in advanced prostate cancer","volume":"31","author":"Ge","year":"2020","journal-title":"Ann. Oncol. : official journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.canlet.2025.217808_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100962","article-title":"Current therapy and drug resistance in metastatic castration-resistant prostate cancer","volume":"68","author":"Cai","year":"2023","journal-title":"Drug Resist. Updates : reviews and commentaries in antimicrobial and anticancer chemotherapy"},{"issue":"5","key":"10.1016\/j.canlet.2025.217808_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006581","article-title":"Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment","volume":"11","author":"Xu","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.canlet.2025.217808_bib10","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/2326-6066.CIR-20-0729","article-title":"Flightless I homolog reverses enzalutamide resistance through PD-L1-mediated immune evasion in prostate cancer","volume":"9","author":"Ruan","year":"2021","journal-title":"Cancer Immunol. Res."},{"issue":"9","key":"10.1016\/j.canlet.2025.217808_bib11","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1158\/2326-6066.CIR-19-0371","article-title":"Enzalutamide, an androgen receptor antagonist, enhances myeloid cell-mediated immune suppression and tumor progression","volume":"8","author":"Consiglio","year":"2020","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.canlet.2025.217808_bib12","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1186\/s12885-024-12298-3","article-title":"Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor","volume":"24","author":"Obinata","year":"2024","journal-title":"BMC cancer"},{"issue":"4","key":"10.1016\/j.canlet.2025.217808_bib13","article-title":"ARID1A mutation: a new target for efficient cancer immunotherapy","volume":"2","author":"Chen","year":"2024","journal-title":"Innovat. Med."},{"issue":"3","key":"10.1016\/j.canlet.2025.217808_bib14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.tcb.2022.06.010","article-title":"Targeting STING to promote antitumor immunity","volume":"33","author":"Chin","year":"2023","journal-title":"Trends Cell Biol."},{"issue":"7","key":"10.1016\/j.canlet.2025.217808_bib15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nri3845","article-title":"Type I interferons in anticancer immunity","volume":"15","author":"Zitvogel","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.canlet.2025.217808_bib16","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00018-022-04219-z","article-title":"Type I interferon-mediated tumor immunity and its role in immunotherapy","volume":"79","author":"Yu","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"issue":"3","key":"10.1016\/j.canlet.2025.217808_bib17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrc.2016.14","article-title":"Antitumour actions of interferons: implications for cancer therapy","volume":"16","author":"Parker","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.canlet.2025.217808_bib18","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1158\/1078-0432.CCR-10-1114","article-title":"Direct effects of type I interferons on cells of the immune system","volume":"17","author":"Hervas-Stubbs","year":"2011","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"issue":"43","key":"10.1016\/j.canlet.2025.217808_bib19","doi-asserted-by":"crossref","first-page":"11482","DOI":"10.1073\/pnas.1705536114","article-title":"Selective neutralization of IL-12 p40 monomer induces death in prostate cancer cells via IL-12-IFN-\u03b3","volume":"114","author":"Kundu","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"15","key":"10.1016\/j.canlet.2025.217808_bib20","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1158\/0008-5472.CAN-12-3464","article-title":"Vaccine-instructed intratumoral IFN-\u03b3 enables regression of autochthonous mouse prostate cancer in allogeneic T-cell transplantation","volume":"73","author":"Hess Michelini","year":"2013","journal-title":"Cancer Res."},{"issue":"14","key":"10.1016\/j.canlet.2025.217808_bib21","doi-asserted-by":"crossref","DOI":"10.1172\/JCI147025","article-title":"FOXA1 overexpression suppresses interferon signaling and immune response in cancer","volume":"131","author":"He","year":"2021","journal-title":"J. Clin. Investig."},{"issue":"9","key":"10.1016\/j.canlet.2025.217808_bib22","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/s41416-021-01435-5","article-title":"Metabolic reprogramming in prostate cancer","volume":"125","author":"Ahmad","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.canlet.2025.217808_bib23","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.canlet.2025.217808_bib24","article-title":"Pathological functions and therapeutic targets of post-translational modifications in pan-cancer","volume":"1","author":"Zhu","year":"2023","journal-title":"Innovat. Med."},{"issue":"6","key":"10.1016\/j.canlet.2025.217808_bib25","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.7150\/thno.82920","article-title":"The role of lipid metabolic reprogramming in tumor microenvironment","volume":"13","author":"Yang","year":"2023","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.canlet.2025.217808_bib26","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1074\/mcp.M112.023887","article-title":"Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression","volume":"12","author":"Saraon","year":"2013","journal-title":"Mol. Cell. Proteomics : MCP"},{"issue":"44","key":"10.1016\/j.canlet.2025.217808_bib27","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1038\/s41388-021-02008-9","article-title":"Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel","volume":"40","author":"Labanca","year":"2021","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.canlet.2025.217808_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25052630","article-title":"Integrative metabolomic analysis of serum and selected serum exosomal microRNA in metastatic castration-resistant prostate cancer","volume":"25","author":"Evin","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.canlet.2025.217808_bib29","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1158\/1535-7163.MCT-20-0244","article-title":"Identification of genes required for enzalutamide resistance in castration-resistant prostate cancer cells in vitro","volume":"20","author":"Kohrt","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"issue":"6","key":"10.1016\/j.canlet.2025.217808_bib30","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.molcel.2020.05.034","article-title":"Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy","volume":"78","author":"Bader","year":"2020","journal-title":"Mol. Cell"},{"issue":"12","key":"10.1016\/j.canlet.2025.217808_bib31","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41577-021-00541-y","article-title":"Metabolic barriers to cancer immunotherapy","volume":"21","author":"DePeaux","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.canlet.2025.217808_bib32","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191920","article-title":"Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells","volume":"217","author":"Manzo","year":"2020","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.canlet.2025.217808_bib33","article-title":"Long-term marine \u03c9-3 polyunsaturated fatty acids intake in relation to incidence of colorectal cancer subclassified by macrophage infiltrates","volume":"2","author":"Ugai","year":"2024","journal-title":"Innovat. Med."},{"issue":"6","key":"10.1016\/j.canlet.2025.217808_bib34","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1158\/1078-0432.CCR-21-3114","article-title":"Circulating immune bioenergetic, metabolic, and genetic signatures predict melanoma patients' response to anti-PD-1 immune checkpoint blockade","volume":"28","author":"Triozzi","year":"2022","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"issue":"1","key":"10.1016\/j.canlet.2025.217808_bib35","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41392-024-01772-w","article-title":"Targeting carnitine palmitoyl transferase 1A (CPT1A) induces ferroptosis and synergizes with immunotherapy in lung cancer","volume":"9","author":"Ma","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"3","key":"10.1016\/j.canlet.2025.217808_bib36","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20211546","article-title":"Tumor-derived OBP2A promotes prostate cancer castration resistance","volume":"220","author":"Jeong","year":"2023","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.canlet.2025.217808_bib37","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2326-6066.CIR-16-0390","article-title":"Prostate cancer cells express more androgen receptor (AR) following androgen deprivation, improving recognition by AR-specific T cells","volume":"5","author":"Olson","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"W1","key":"10.1016\/j.canlet.2025.217808_bib38","doi-asserted-by":"crossref","first-page":"W212","DOI":"10.1093\/nar\/gkz446","article-title":"ChEA3: transcription factor enrichment analysis by orthogonal omics integration","volume":"47","author":"Keenan","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"10.1016\/j.canlet.2025.217808_bib39","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nrc4036","article-title":"Metabolism: MYC clocks on","volume":"15","author":"McCarthy","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.canlet.2025.217808_bib40","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1152\/physrev.00025.2005","article-title":"Transcriptional regulation of metabolism","volume":"86","author":"Desvergne","year":"2006","journal-title":"Physiol. Rev."},{"issue":"12","key":"10.1016\/j.canlet.2025.217808_bib41","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1002\/ijc.32218","article-title":"Prospective serum metabolomic profiling of lethal prostate cancer","volume":"145","author":"Huang","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2025.217808_bib42","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s12967-022-03478-5","article-title":"Identification of characteristic metabolic panels for different stages of prostate cancer by (1)H NMR-based metabolomics analysis","volume":"20","author":"Zhang","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2025.217808_bib43","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.2147\/OTT.S238975","article-title":"miR-106b-5p inhibits IRF1\/IFN-\u03b2 signaling to promote M2 macrophage polarization of glioblastoma","volume":"13","author":"Shi","year":"2020","journal-title":"OncoTargets Ther."},{"issue":"12","key":"10.1016\/j.canlet.2025.217808_bib44","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/s41419-024-07268-3","article-title":"\u03b2-Hydroxybutyrate suppresses M1 macrophage polarization through \u03b2-hydroxybutyrylation of the STAT1 protein","volume":"15","author":"Bai","year":"2024","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.canlet.2025.217808_bib45","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12916-022-02352-x","article-title":"Ketone body \u03b2-hydroxybutyrate ameliorates colitis by promoting M2 macrophage polarization through the STAT6-dependent signaling pathway","volume":"20","author":"Huang","year":"2022","journal-title":"BMC Med."},{"issue":"1","key":"10.1016\/j.canlet.2025.217808_bib46","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41392-022-01252-z","article-title":"Multifaceted functions of STING in human health and disease: from molecular mechanism to targeted strategy","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"1","key":"10.1016\/j.canlet.2025.217808_bib47","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s00125-020-05305-2","article-title":"\u03b2-Hydroxybutyrate inhibits histone deacetylase 3 to promote claudin-5 generation and attenuate cardiac microvascular hyperpermeability in diabetes","volume":"64","author":"Li","year":"2021","journal-title":"Diabetologia"},{"issue":"6116","key":"10.1016\/j.canlet.2025.217808_bib48","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1126\/science.1227166","article-title":"Suppression of oxidative stress by \u03b2-hydroxybutyrate, an endogenous histone deacetylase inhibitor","volume":"339","author":"Shimazu","year":"2013","journal-title":"Science (New York, N.Y.)"},{"issue":"7","key":"10.1016\/j.canlet.2025.217808_bib49","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28966","article-title":"HBV confers innate immune evasion through triggering HAT1\/acetylation of H4K5\/H4K12\/miR-181a-5p or KPNA2\/cGAS-STING\/IFN-I signaling","volume":"95","author":"Zhao","year":"2023","journal-title":"J. Med. Virol."},{"issue":"2","key":"10.1016\/j.canlet.2025.217808_bib50","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.molcel.2016.03.036","article-title":"Metabolic regulation of gene expression by histone lysine \u03b2-hydroxybutyrylation","volume":"62","author":"Xie","year":"2016","journal-title":"Mol. Cell"},{"issue":"2","key":"10.1016\/j.canlet.2025.217808_bib51","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrm.2016.140","article-title":"Metabolic regulation of gene expression through histone acylations","volume":"18","author":"Sabari","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"9","key":"10.1016\/j.canlet.2025.217808_bib52","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe2771","article-title":"The regulatory enzymes and protein substrates for the lysine \u03b2-hydroxybutyrylation pathway","volume":"7","author":"Huang","year":"2021","journal-title":"Sci. Adv."},{"issue":"9","key":"10.1016\/j.canlet.2025.217808_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111724","article-title":"\u03b2-hydroxybutyrate reduces reinstatement of cocaine conditioned place preference through hippocampal CaMKII-\u03b1 \u03b2-hydroxybutyrylation","volume":"41","author":"Li","year":"2022","journal-title":"Cell Rep."},{"issue":"11","key":"10.1016\/j.canlet.2025.217808_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2023.100659","article-title":"Proteomics and \u03b2-hydroxybutyrylation modification characterization in the hearts of naturally senescent mice","volume":"22","author":"Yang","year":"2023","journal-title":"Mol. Cell. Proteomics"},{"issue":"10","key":"10.1016\/j.canlet.2025.217808_bib55","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/ni.3558","article-title":"Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing","volume":"17","author":"Chen","year":"2016","journal-title":"Nat. Immunol."},{"issue":"9","key":"10.1016\/j.canlet.2025.217808_bib56","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41580-020-0244-x","article-title":"Molecular mechanisms and cellular functions of cGAS-STING signalling","volume":"21","author":"Hopfner","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"9","key":"10.1016\/j.canlet.2025.217808_bib57","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41577-021-00524-z","article-title":"The cGAS-STING pathway as a therapeutic target in inflammatory diseases","volume":"21","author":"Decout","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"16","key":"10.1016\/j.canlet.2025.217808_bib58","doi-asserted-by":"crossref","DOI":"10.15252\/embj.201798701","article-title":"Cezanne\/OTUD7B is a cell cycle-regulated deubiquitinase that antagonizes the degradation of APC\/C substrates","volume":"37","author":"Bonacci","year":"2018","journal-title":"EMBO J."},{"issue":"6\u20137","key":"10.1016\/j.canlet.2025.217808_bib59","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1080\/15384101.2019.1593646","article-title":"Impressionist portraits of mitotic exit: APC\/C, K11-linked ubiquitin chains and Cezanne","volume":"18","author":"Bonacci","year":"2019","journal-title":"Cell Cycle"},{"issue":"2","key":"10.1016\/j.canlet.2025.217808_bib60","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41556-023-01339-x","article-title":"Innate immune sensing of lysosomal dysfunction drives multiple lysosomal storage disorders","volume":"26","author":"Wang","year":"2024","journal-title":"Nat. Cell Biol."},{"issue":"Pt 2","key":"10.1016\/j.canlet.2025.217808_bib61","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.semcancer.2020.03.001","article-title":"APC\/C ubiquitin ligase: functions and mechanisms in tumorigenesis","volume":"67","author":"Schrock","year":"2020","journal-title":"Semin. Cancer Biol."},{"issue":"7","key":"10.1016\/j.canlet.2025.217808_bib62","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.tcb.2019.03.001","article-title":"APC\/C ubiquitin ligase: coupling cellular differentiation to G1\/G0 phase in multicellular systems","volume":"29","author":"Kimata","year":"2019","journal-title":"Trends Cell Biol."},{"issue":"7","key":"10.1016\/j.canlet.2025.217808_bib63","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nrm3132","article-title":"Cubism and the cell cycle: the many faces of the APC\/C","volume":"12","author":"Pines","year":"2011","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.canlet.2025.217808_bib64","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/nrclinonc.2010.136","article-title":"Drug resistance in metastatic castration-resistant prostate cancer","volume":"8","author":"Seruga","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217808_bib65","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","article-title":"Treatment of advanced prostate cancer","volume":"70","author":"Teo","year":"2019","journal-title":"Annu. Rev. Med."},{"issue":"11","key":"10.1016\/j.canlet.2025.217808_bib66","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.ccell.2023.10.006","article-title":"Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer","volume":"41","author":"Hawley","year":"2023","journal-title":"Cancer cell"},{"issue":"13","key":"10.1016\/j.canlet.2025.217808_bib67","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1158\/1078-0432.CCR-19-3372","article-title":"T-cell infiltration and adaptive Treg resistance in response to androgen deprivation with or without vaccination in localized prostate cancer","volume":"26","author":"Obradovic","year":"2020","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"issue":"3","key":"10.1016\/j.canlet.2025.217808_bib68","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001556","article-title":"Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer","volume":"9","author":"Madan","year":"2021","journal-title":"Journal for immunotherapy of cancer"},{"issue":"4","key":"10.1016\/j.canlet.2025.217808_bib69","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1158\/1078-0432.CCR-17-2006","article-title":"PTEN loss promotes intratumoral androgen synthesis and tumor microenvironment remodeling via aberrant activation of RUNX2 in castration-resistant prostate cancer","volume":"24","author":"Yang","year":"2018","journal-title":"Clin. Cancer Res. : an official journal of the American Association for Cancer Research"},{"issue":"22","key":"10.1016\/j.canlet.2025.217808_bib70","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1200\/JCO.23.00233","article-title":"Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase III KEYLYNK-010 trial","volume":"41","author":"Antonarakis","year":"2023","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"issue":"7","key":"10.1016\/j.canlet.2025.217808_bib71","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"The Lancet. Oncology"},{"issue":"1","key":"10.1016\/j.canlet.2025.217808_bib72","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","article-title":"Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer","volume":"35","author":"Beer","year":"2017","journal-title":"J. Clin. Oncol. : official journal of the American Society of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.canlet.2025.217808_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10930-017-9696-z","article-title":"Phosphorylation: implications in cancer","volume":"36","author":"Singh","year":"2017","journal-title":"Protein J."},{"issue":"5","key":"10.1016\/j.canlet.2025.217808_bib74","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41580-021-00441-y","article-title":"Modulation of cellular processes by histone and non-histone protein acetylation","volume":"23","author":"Shvedunova","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"8","key":"10.1016\/j.canlet.2025.217808_bib75","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/ijc.34288","article-title":"Out of the cycle: impact of cell cycle aberrations on cancer metabolism and metastasis","volume":"152","author":"Cheung","year":"2023","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.canlet.2025.217808_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.165715","article-title":"Cell cycle regulators in cancer cell metabolism","volume":"1866","author":"Leal-Esteban","year":"2020","journal-title":"Biochimica et biophysica acta. Molecular basis of disease"},{"issue":"1","key":"10.1016\/j.canlet.2025.217808_bib77","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41422-020-0372-z","article-title":"Skp2 dictates cell cycle-dependent metabolic oscillation between glycolysis and TCA cycle","volume":"31","author":"Liu","year":"2021","journal-title":"Cell Res."},{"issue":"2","key":"10.1016\/j.canlet.2025.217808_bib78","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.tcb.2023.05.012","article-title":"The bidirectional relationship between metabolism and cell cycle control","volume":"34","author":"Diehl","year":"2024","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.canlet.2025.217808_bib79","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1146\/annurev-cellbio-092910-154010","article-title":"Driving the cell cycle through metabolism","volume":"28","author":"Cai","year":"2012","journal-title":"Annu. Rev. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.canlet.2025.217808_bib80","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bbcan.2018.06.005","article-title":"Metabolic reprogramming for cancer cells and their microenvironment: beyond the Warburg Effect","volume":"1870","author":"Sun","year":"2018","journal-title":"Biochimica et biophysica acta. Reviews on cancer"},{"issue":"1","key":"10.1016\/j.canlet.2025.217808_bib81","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","article-title":"The emerging hallmarks of cancer metabolism","volume":"23","author":"Pavlova","year":"2016","journal-title":"Cell Metab."},{"issue":"5","key":"10.1016\/j.canlet.2025.217808_bib82","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1158\/2159-8290.CD-20-1211","article-title":"Metabolic codependencies in the tumor microenvironment","volume":"11","author":"Dey","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2025.217808_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217694","article-title":"Metformin inhibits the progression of castration resistant prostate cancer by regulating PDE6D induced purine metabolic alternation and cGMP\/PKG pathway activation","author":"Cai","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217808_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217441","article-title":"Metabolic reprogramming, malignant transformation and metastasis: lessons from chronic lymphocytic leukaemia and prostate cancer","volume":"611","author":"Hindes","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217808_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217286","article-title":"Evaluation of glucocorticoid-related genes reveals GPD1 as a therapeutic target and regulator of sphingosine 1-phosphate metabolism in CRPC","volume":"605","author":"Liu","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217808_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217355","article-title":"PAF1-mediated transcriptional reprogramming confers docetaxel resistance in advanced prostate cancer","volume":"609","author":"Muniyan","year":"2025","journal-title":"Cancer Lett."},{"issue":"13","key":"10.1016\/j.canlet.2025.217808_bib87","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.7150\/jca.86940","article-title":"circROBO1 promotes prostate cancer growth and enzalutamide resistance via accelerating glycolysis","volume":"14","author":"Zhou","year":"2023","journal-title":"J. Cancer"},{"issue":"4","key":"10.1016\/j.canlet.2025.217808_bib88","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jhep.2024.05.007","article-title":"Targeting OXCT1-mediated ketone metabolism reprograms macrophages to promote antitumor immunity via CD8(+) T cells in hepatocellular carcinoma","volume":"81","author":"Zhu","year":"2024","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.canlet.2025.217808_bib89","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/neuonc\/noad232","article-title":"Metabolic modulation of histone acetylation mediated by HMGCL activates the FOXM1\/\u03b2-catenin pathway in glioblastoma","volume":"26","author":"Sun","year":"2024","journal-title":"Neuro Oncol."},{"issue":"9","key":"10.1016\/j.canlet.2025.217808_bib90","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2021110466","article-title":"Ketogenic HMG-CoA lyase and its product \u03b2-hydroxybutyrate promote pancreatic cancer progression","volume":"41","author":"Gouirand","year":"2022","journal-title":"EMBO J."},{"issue":"10","key":"10.1016\/j.canlet.2025.217808_bib91","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/j.cmet.2023.09.001","article-title":"Ketogenesis promotes tolerance to Pseudomonas aeruginosa pulmonary infection","volume":"35","author":"Tomlinson","year":"2023","journal-title":"Cell Metab."},{"issue":"3","key":"10.1016\/j.canlet.2025.217808_bib92","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.tem.2024.01.006","article-title":"Ketogenesis favors oxidative phosphorylation to promote disease tolerance","volume":"35","author":"Jesus","year":"2024","journal-title":"Trends Endocrinol. Metabol.: TEM (Trends Endocrinol. Metab.)"},{"issue":"10","key":"10.1016\/j.canlet.2025.217808_bib93","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.cmet.2024.08.005","article-title":"SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8(+) T cell activation","volume":"36","author":"Liu","year":"2024","journal-title":"Cell Metab."},{"issue":"10","key":"10.1016\/j.canlet.2025.217808_bib94","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1158\/0008-5472.CAN-23-2742","article-title":"Ketogenic diet alters the epigenetic and immune landscape of prostate cancer to overcome resistance to immune checkpoint blockade therapy","volume":"84","author":"Murphy","year":"2024","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.canlet.2025.217808_bib95","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.145207","article-title":"Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade","volume":"6","author":"Ferrere","year":"2021","journal-title":"JCI insight"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525003751?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525003751?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T20:25:07Z","timestamp":1755894307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525003751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":95,"alternative-id":["S0304383525003751"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217808","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ketogenesis instigates immune suppression in enzalutamide resistant prostate cancer via OTUD7B \u03b2-hydroxybutyrylation","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217808","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"217808"}}